BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32345074)

  • 1. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
    Deligiorgi MV; Panayiotidis MI; Trafalis DT
    Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
    González-Rodríguez E; Rodríguez-Abreu D;
    Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endocrine side effects of cancer immunotherapy].
    Kroiß M; Schilling B; Deutschbein T
    Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB; Bastholt L; Yderstræde K
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
    Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.
    Illouz F; Briet C; Cloix L; Le Corre Y; Baize N; Urban T; Martin L; Rodien P
    Cancer Med; 2017 Aug; 6(8):1923-1929. PubMed ID: 28719055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
    Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
    Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.